All Pharmaceutical Microbiology articles – Page 15
-
NewsEngineered virus boosts immune response against glioblastoma in preclinical models
Researchers have modified a herpes simplex virus (HSV-1) that stimulates the immune system to attack glioblastoma cells. A single dose of the modified virus increased T-cell, natural killer cell, and myeloid cell responses in the tumor microenvironment and increased the overall survival in preclinical models.
-
NewsSocial lives of viruses affect antiviral resistance
Interactions among viruses can help them succeed inside their hosts or impart vulnerabilities that make them easier to treat. Scientists are learning the ways viruses mingle inside the cells they infect, as well as the consequences of their socializing.
-
NewsPlant phenolic acids supercharge old antibiotics against multidrug resistant E. coli
Plant derived phenolic acids can dramatically enhance the activity of existing antibiotics against multidrug resistant E. coli, offering a promising new tool in the global fight against antimicrobial resistance.
-
NewsStudy shows robust immune responses to H5N8 avian influenza vaccine
A new study shows that the MF59-adjuvanted A(H5N8) vaccine induced strong immune responses, including both functional antibodies and memory T-cell responses, against the vaccine virus, as well as against H5 viruses that have caused recent outbreaks in Europe and the United States.
-
NewsChemists synthesize a fungal compound that holds promise for treating brain cancer
For the first time, chemists have synthesized a fungal compound known as verticillin A, which was discovered more than 50 years ago and has shown potential as an anticancer agent.
-
NewsLight-sensitive microbial protein may herald new cancer therapies
Researchers used a mouse cancer model to show that tumors expressing Archaerhodopsin 3 shrink after exposure to green light.
-
NewsCommon water pill may help HIV medicines work faster and reduce inflammation, early study suggests
Adding a readily available diuretic to standard HIV therapy appears to reduce circulating virus by four-fold, a new study shows. Researchers treated HIV-infected mice with human immune cells with first‑line antiretroviral therapy plus a long‑acting form of spironolactone.
-
NewsResearchers rescue antibiotics from resistance using phototherapy
Researchers have used phototherapy to inhibit a protein in E. coli bacteria that makes them resistant to antibiotics. This new method, if proven safe and effective in living organisms, holds promise for rescuing the effectiveness of antibiotics that bacteria have become resistant to.
-
NewsA viral fitness-constraint strategy exploits the structural and functional limitations of viral evolution
Researchers have revealed two innovative strategies for the development of durable and broadly neutralizing antibodies against SARS-CoV-2. Their study proposes the immune trajectory strategy and the viral fitness-constraint strategy.
-
NewsCorticosteroid use does not appear to increase infectious complications in non-COVID-19 pneumonia
A systematic review and meta-analysis found that adjunct corticosteroids probably reduce short-term mortality in cases of severe pneumonia and acute respiratory distress syndrome and may reduce secondary shock in severe pneumonia.
-
NewsUnder The Lens: Callum Cooper explores how bacteriophages could revolutionise medicine - and how we get to that point
In a compelling new video interview from Applied Microbiology International’s ‘Under the Lens’ series, Dr. Callum Cooper shares fascinating insights into one of medicine’s most promising frontiers: phage therapy.
-
NewsNew guideline on pre-exposure and postexposure HIV prevention
Multiple pre-exposure (PrEP) and postexposure (PEP) treatments are now available to prevent HIV infection. An updated Canadian guideline contains 31 recommendations and 10 good practice statements to help clinicians and other health care professionals offer these options to patients.
-
NewsGlobal Virus Network issues warning on the Marburg virus outbreak in Ethiopia
The Global Virus Network (GVN) has issued a statement on the newly confirmed outbreak of Marburg virus disease (MVD) in southern Ethiopia. This represents the country’s first documented outbreak of Marburg virus and raises urgent public health, research, and surveillance imperatives.
-
NewsFractional-dose vaccines can save millions during shortages
New research shows that using smaller, fractional doses of vaccines can significantly reduce infections during epidemics, especially when vaccine supply, delivery, or administration capacity is limited.
-
NewsCuring hepatitis C can rebalance immunity in Indonesians living with HIV
A new study provides the first longitudinal immunological data on HIV/HCV-coinfected individuals in Southeast Asia, underscoring the importance of early hepatitis C treatment to prevent long-term immune and liver complications.
-
NewsParkinson’s drug offers basis for new hospital bacterium anti-infectives
Researchers have discovered a promising starting point for the development of new active substances against the hospital germ Pseudomonas aeruginosa.
-
NewsExperimental mRNA therapy shows potential to combat antibiotic-resistant infections
Researchers have reported early success with a novel mRNA-based therapy designed to combat antibiotic-resistant bacteria. In preclinical studies, the therapy slowed bacterial growth, strengthened immune cell activity, and reduced lung tissue damage in models of multidrug-resistant pneumonia.
-
NewsNew collection of bacteria-eating viruses can tackle hospital superbug
An international team of researchers have comprehensively catalogued a new collection of bacteria-eating viruses called phages sourced, in part, from hospital wastewater. The phages have been shown to be effective against different strains of Klebsiella pneumoniae.
-
NewsSnakebites: COVID vaccine tech could limit venom damage
The same technology used in COVID-19 vaccines could help prevent muscle damage from snakebites, according to scientists who say it could be even more useful for other conditions where toxins cause harm gradually, such as blocking harmful toxins produced by bacteria during infections.
-
NewsScientists uncover how COVID-19 variants outsmart the immune system
Researchers have created the most comprehensive map to date showing how antibodies attach to the SARS-CoV-2 virus, which causes COVID-19, and how viral mutations weaken that attachment.